Current Effect of“4+7”Drug Centralized Volume Procurement and Suggestions for Future Improvement

Objective To explore the impact of the“4+7”city drug centralized procurement policy implemented from April 1st,2019 on China’s pharmaceutical market and the differences between this pilot scheme and the first volume procurement,so as to put forward some suggestions for this policy and improve the drug price formation mechanism.Methods The characteristics of the“4+7”volume procurement policy and its improvements were summarized through literature research,and the distribution of the winning enterprises in volume procurement was shown by the chart.Then the overall situation of pharmaceutical enterprises in China was analyzed.Results and Conclusion According to the main distribution of enterprises in the alliance region,we can see that the first round of bid-winning enterprises with 25 varieties are mainly distributed in the eastern coastal cities of Jiangsu,Zhejiang,Shandong,and Guangdong,which shows a trend of developing to provinces of Sichuan,Hubei,and Hunan.With the increase of volume procurement inland cities will be included in the future.This pilot scheme of volume procurement is a reform of the entire pharmaceutical industry.It has improved the market structure and promoted the transformation and upgrading of regional medicine representatives.The most important thing is to enable the public to better enjoy the benefits brought by the low-priced drugs.However,for some pharmaceutical enterprises and drug retail industry,it is a challenge.Therefore,it is necessary to improve the policy and strengthen market supervision and management.

The Status Quo and Countermeasures of“4+7”Quantity Purchase in China

Objective To understand the effectiveness and problems of centralized drug procurement in China by analyzing the implementation of the“4+7”pilot work for centralized drug procurement in China.Methods The current situation and existing problems of drug procurement in China were analyzed through the literature research method.Results and Conclusion At present,good social benefits have been achieved for China’s drug procurement through pilot projects in several cities,but there are some serious problems.The proposed countermeasures will help to improve the procurement of pharmaceuticals in China.

Effects of drug procurement under cap price policy in Sanming

To study the effects of drug procurement under cap price policy (DPUCP)in Sanming,changes in drug category,price, availability and corporate structure were analyzed using purchasing data of the 7th and 8th centralized drug procurement in Fujian Province and the 1st drug procurement under cap price in Sanming,and a field investigation was conducted.(1)The amounts of bid-winning drugs and pharmaceutical makers decreased sharply,leading to optimization of drug category and supplier structure. (2)The procurement could meet clinical demands,though a small percentage of drugs were out of stock.(3)Drug prices fell in general,with 10%decline in domestic drugs with a unit package price over RMB 5yuan,a slight price reduction in imported drugs,and some price increase in cheap domestic drugs with a unit package price under RMB 3yuan.DPUCP policy in Sanming optimized procurement drug category and supplier structure,reduced price,and improved industrial structure.However,problems still existed,such as shortage of some drugs and little price reduction in imported and brand-name drugs.